Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  ACS Chemical Neuroscience

• Publication date

  2018-02-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/acschemneuro.8b00015PMID 29460617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Microtubule-Associated Protein Tau

  2020cited by this paper
• Mutant Huntingtin Disrupts the Nuclear Pore Complex.

  2017cited by this paper
• Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities.

  2017cited by this paper
• Calcium-dependent O-GlcNAc signaling drives liver autophagy in adaptation to starvation

  2017cited by this paper
• Chemical Modulation of Protein O-GlcNAcylation via OGT Inhibition Promotes Human Neural Cell Differentiation.

  2017cited by this paper
• Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

  2017cited by this paper
• O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson’s disease

  2017cited by this paper
• 18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

  2017cited by this paper
• O-GlcNAcylation of ATG4B positively regulates autophagy by increasing its hydroxylase activity

  2016cited by this paper
• O2‐13‐04: Early Clinical Results and Preclinical Validation of the O‐Glcnacase (OGA) Inhibitor Mk‐8719 as a Novel Therapeutic for the Treatment of Tauopathies

  2016cited by this paper
• O-GlcNAc modification is essential for the regulation of autophagy in Drosophila melanogaster

  2015cited by this paper
• mTOR: a pharmacologic target for autophagy regulation.

  2015cited by this paper
• Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

  2015cited by this paper
• Tau post-translational modifications in wildtype and human amyloid precursor protein transgenic mice

  2015cited by this paper
• Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

  2015cited by this paper
• Regulation of Ischemic Neuronal Death by E2F4-p130 Protein Complexes*

  2014cited by this paper
• A Super-Ecliptic, pHluorin-mKate2, Tandem Fluorescent Protein-Tagged Human LC3 for the Monitoring of Mammalian Autophagy

  2014cited by this paper
• Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice

  2014cited by this paper
• Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.

  2014cited by this paper
• New autophagy reporter mice reveal dynamics of proximal tubular autophagy.

  2014cited by this paper
• O-GlcNAc-modification of SNAP-29 regulates autophagosome maturation

  2014cited by this paper
• Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.

  2014cited by this paper
• Cross-talk between Two Essential Nutrient-sensitive Enzymes

  2014cited by this paper
• Decreased O-Linked GlcNAcylation Protects from Cytotoxicity Mediated by Huntingtin Exon1 Protein Fragment*

  2014cited by this paper
• Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart.

  2013cited by this paper
• Increasing Brain Protein O-GlcNAc-ylation Mitigates Breathing Defects and Mortality of Tau.P301L Mice

  2013cited by this paper
• Nutrient-driven O-GlcNAc cycling influences autophagic flux and neurodegenerative proteotoxicity

  2013cited by this paper
• Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice

  2013cited by this paper
• O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment.

  2013cited by this paper
• Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease.

  2013cited by this paper
• Rapamycin increases survival in ALS mice lacking mature lymphocytes

  2013cited by this paper
• Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

  2012cited by this paper
• Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

  2012cited by this paper
• Aging brain microenvironment decreases hippocampal neurogenesis through Wnt‐mediated survivin signaling

  2012cited by this paper
• Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy

  2012cited by this paper
• Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

  2012cited by this paper
• Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

  2012cited by this paper
• Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.

  2011cited by this paper
• Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease

  2011cited by this paper
• Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis

  2011cited by this paper
• Eaten alive: a history of macroautophagy

  2010cited by this paper
• Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis

  2010cited by this paper
• Autophagy gone awry in neurodegenerative diseases

  2010cited by this paper
• Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

  2010cited by this paper
• A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.

  2008cited by this paper
• Culturing hippocampal neurons

  2006cited by this paper
• The potential role of tau protein O-glycosylation in Alzheimer's disease

  2004cited by this paper
• O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.

  2004cited by this paper
• Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

  2003cited by this paper
• Post-translational Modifications of Three Members of the Human MAP1LC3 Family and Detection of a Novel Type of Modification for MAP1LC3B*

  2003cited by this paper
• Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization.

  2003cited by this paper
• Dynamic O-Glycosylation of Nuclear and Cytosolic Proteins

  2002cited by this paper
• Dynamic O-Glycosylation of Nuclear and Cytosolic Proteins

  2001cited by this paper
• Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts.

  2000cited by this paper
• Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

  2000cited by this paper
• Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

  1998cited by this paper
• Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

  1998cited by this paper
• O-Linked GlcNAc Transferase Is a Conserved Nucleocytoplasmic Protein Containing Tetratricopeptide Repeats*

  1997cited by this paper
• The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine*

  1996cited by this paper
• β‐Amyloid precursor protein is modified with O‐linked N‐acetylglucosamine

  1995cited by this paper
• The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

  1987cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels.

  1985cited by this paper
• Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc.

  1984cited by this paper

• Pharmacological inhibition of O-GlcNAcase reduces pS129-α-synuclein positive aggregates in the substantia nigra of mThy1-hSNCA mice.

  2026cites this paper
• Landscape of Protein Post-Translational Modifications in Age-Related Neurodegenerative Disorders: Implications in Protein Aggregation, Altered Cellular Processes, and Therapeutics.

  2026cites this paper
• Regulation of autophagy: Insights into O-GlcNAc modification mechanisms.

  2025cites this paper
• O-GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review)

  2025cites this paper
• Twenty years of therapeutic development in tauopathy mouse models: a scoping review

  2025cites this paper
• O-GlcNAcylation-regulated classical programmed cell death in diseases: molecular crosstalk and therapeutic opportunities

  2025cites this paper
• Differences in intrinsic cellular O-GlcNAcylation impact response to metabolic stress

  2025cites this paper
• Targeting O-GlcNAcylation: Novel Therapeutic Strategies for Neurological Disease

  2025cites this paper
• O-GlcNAc impacts mitophagy via the PINK1-dependent pathway

  2024cites this paper
• Diaminocyclopentane - l-Lysine Adducts: Potent and selective inhibitors of human O-GlcNAcase.

  2024cites this paper
• The multifaceted role of intracellular glycosylation in cytoprotection and heart disease

  2024cites this paper
• Redox imbalance and metabolic defects in the context of Alzheimer disease

  2024cites this paper
• O-GlcNAcylation and Its Roles in Neurodegenerative Diseases

  2024cites this paper
• An Efficient and Accessible Hectogram-Scale Synthesis for the Selective O-GlcNAcase Inhibitor Thiamet-G

  2024cites this paper
• Opportunities for Therapeutic Modulation of O-GlcNAc

  2024cites this paper
• Heat ‘n Beat: A universal high-throughput end-to-end proteomics sample processing platform in under an hour

  2023cites this paper
• O-GlcNAc regulates the mitochondrial integrated stress response by regulating ATF4

  2023cites this paper
• Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases

  2023influential citation
• Inhibition of O-GlcNAcylation Reduces Cell Viability and Autophagy and Increases Sensitivity to Chemotherapeutic Temozolomide in Glioblastoma

  2023cites this paper
• Relationships between gene expression and behavior in mice in response to systemic modulation of the O‐GlcNAcylation pathway

  2023cites this paper
• Swainsonine inhibits autophagic degradation and causes cytotoxicity by reducing CTSD O-GlcNAcylation.

  2023cites this paper
• Highly functionalized diaminocyclopentanes: A new route to potent and selective inhibitors of human O-GlcNAcase.

  2023cites this paper
• Carbohydrate-derived bicyclic selenazolines as new dual inhibitors (cholinesterases/OGA) against Alzheimer's disease.

  2022cites this paper
• Acute inhibition of OGA sex-dependently alters the networks associated with bioenergetics, autophagy, and neurodegeneration

  2022cites this paper
• Deglycosylated EpCAM regulates proliferation by enhancing autophagy of breast cancer cells via PI3K/Akt/mTOR pathway

  2022cites this paper
• Chemical Biology Approaches to Understanding Neuronal O–GlcNAcylation

  2022cites this paper
• Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies

  2022cites this paper
• O-GlcNAcylation stabilizes the autophagy-initiating kinase ULK1 by inhibiting chaperone-mediated autophagy upon HPV infection

  2022cites this paper
• Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease

  2021cites this paper
• Comparison of N-Acetyl-Glucosamine to Other Monosaccharides Reveals Structural Differences for the Inhibition of α-Synuclein Aggregation.

  2021cites this paper
• Monitoring and modulating O-GlcNAcylation: assays and inhibitors of O-GlcNAc processing enzymes.

  2021cites this paper
• Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis

  2021cites this paper
• Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

  2021cites this paper
• New Insights Into the Biology of Protein O-GlcNAcylation: Approaches and Observations

  2021cites this paper
• Post-translational modifications: Regulators of neurodegenerative proteinopathies.

  2021cites this paper
• High-Fat Diet Leads to Reduced Protein O-GlcNAcylation and Mitochondrial Defects Promoting the Development of Alzheimer’s Disease Signatures

  2021cites this paper
• Sweet tailoring of glyco-modulatory extracellular matrix-inspired biomaterials to target neuroinflammation

  2021cites this paper
• Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders.

  2021cites this paper
• REM Sleep Deprivation Impairs Learning and Memory by Decreasing Brain O-GlcNAc Cycling in Mouse

  2021cites this paper
• Polysiloxane-based Ratiometric Fluorescent Probe for Monitoring Lysosomal Autophagy Pathway in Three Distinguishable Channels

  2021cites this paper
• The comprehensive mechanistic insight into the effects of vitamin D on dementia – a review

  2021cites this paper
• Chemerin regulates autophagy to participate in polycystic ovary syndrome

  2021cites this paper
• Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles

  2021cites this paper
• The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome

  2020cites this paper
• The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome

  2020cites this paper
• Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.

  2020cites this paper
• The Glucose Metabolic Pathway as A Potential Target for Therapeutics: Crucial Role of Glycosylation in Alzheimer’s Disease

  2020cites this paper
• Role of O-Linked N-acetylglucosamine (O-GlcNAc) Protein Modification in Cellular (Patho)Physiology.

  2020cites this paper
• OGT knockdown counteracts high phosphate-induced vascular calcification in chronic kidney disease through autophagy activation by downregulating YAP.

  2020cites this paper
• MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

  2020cites this paper
• Pharmacological inhibition and knockdown of O‐GlcNAcase reduces cellular internalization of α‐synuclein preformed fibrils

  2020cites this paper
• Molecular Interrogation to Crack the Case of O-GlcNAc.

  2020cites this paper
• Acutely elevated O-GlcNAcylation suppresses hippocampal activity by modulating both intrinsic and synaptic excitability factors

  2019cites this paper
• O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.

  2019cites this paper
• Modulation of O-GlcNAcylation Regulates Autophagy in Cortical Astrocytes

  2019cites this paper
• Exploring the bi‐directional relationship between autophagy and Alzheimer’s disease

  2019cites this paper
• Discovery of MK-8719, A Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.

  2019cites this paper
• Apolipoprotein A-I improves hepatic autophagy through the AMPK pathway.

  2019cites this paper
• Amyloid β‐induced elevation of O‐GlcNAcylated c‐Fos promotes neuronal cell death

  2018cites this paper
• Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.

  2018cites this paper
• Modification of the Thioglycosyl-Naphthalimides as Potent and Selective Human O-GlcNAcase Inhibitors.

  2018cites this paper
• Therapeutic Strategies Targeting Tau Protein : Implications for Alzheimer ’ s Disease 1 MedDocs eBooks

  2018cites this paper